Precision medicine’s blind spot: Rebalancing the evidence base to reflect women’s health
Chloe E. Bird, Hamad Al Ibrahim · 2026
Read Precision medicine’s blind spot: Rebalancing the evidence base to reflect women’s health by Chloe E. Bird, Hamad Al Ibrahim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13251823.txt.
Description
Chloe Bird and Hamad Al Ibrahim argue that precision medicine has a blind spot in this 2026 commentary. Care tailored to each person's biology still rests on evidence built mostly from male bodies, a legacy of decades of excluding women from early research.
The authors trace policy milestones, from a 1977 rule that pushed women out of early drug trials to later laws requiring their inclusion. Even so, only about nine percent of United States federal research funding from 2013 to 2023 targeted women's health. Women made up about 41 percent of trial participants in a recent large sample. They demand reforms in funding, design, and sex-split reporting.
Catalog record
| CREATOR | Chloe E. Bird, Hamad Al Ibrahim |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9406 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |